Zevra Therapeutics Inc (NASDAQ: ZVRA) on Monday, plunged -6.11% from the previous trading day, before settling in for the closing price of $6.22. Within the past 52 weeks, ZVRA’s price has moved between $3.89 and $7.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 44.97% over the last five years. The company achieved an average annual earnings per share of -14.87%. With a float of $41.52 million, this company’s outstanding shares have now reached $41.53 million.
The firm has a total of 69 workers. Let’s measure their productivity.
Zevra Therapeutics Inc (ZVRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zevra Therapeutics Inc is 0.79%, while institutional ownership is 33.23%. The most recent insider transaction that took place on Jul 17 ’24, was worth 13,540. In this transaction CFO & Treasurer of this company bought 2,000 shares at a rate of $6.77, taking the stock ownership to the 18,469 shares. Before that another transaction happened on Jul 16 ’24, when Company’s Director bought 10,000 for $6.81, making the entire transaction worth $68,065. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -14.87% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Zevra Therapeutics Inc (ZVRA) is currently performing well based on its current performance indicators. A quick ratio of 2.10 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.35, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Analysing the last 5-days average volume posted by the [Zevra Therapeutics Inc, ZVRA], we can find that recorded value of 0.46 million was better than the volume posted last year of 0.27 million. As of the previous 9 days, the stock’s Stochastic %D was 27.75%. Additionally, its Average True Range was 0.39.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 59.64%, which indicates a significant increase from 23.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.04% in the past 14 days, which was higher than the 58.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.08, while its 200-day Moving Average is $5.25. Now, the first resistance to watch is $6.19. This is followed by the second major resistance level at $6.53. The third major resistance level sits at $6.74. If the price goes on to break the first support level at $5.64, it is likely to go to the next support level at $5.43. Should the price break the second support level, the third support level stands at $5.09.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
Market capitalization of the company is 244.40 million based on 41,853K outstanding shares. Right now, sales total 27,460 K and income totals -46,050 K. The company made 3,430 K in profit during its latest quarter, and -16,620 K in sales during its previous quarter.
